Evidence map›Paper›PMID 40289988›Full record

ArticleCurrent stem cell research & therapy2025

Human Wharton's Jelly Mesenchymal Stem Cells and their Extracellular Vesicles in the Management of Bleomycin-induced Lung Injury in Model Animals: A Comparative Preclinical Study Focused on Histomorphometric Analysis.

Anand Krishnan, Harikrishnan Vijayakumar Sreelatha, Sabareeswaran Arumugam, Naresh Kasoju

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in Current stem cell research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Anand KrishnanDivision of Tissue Culture, Department of Applied Biology, Biomedical Technology Wing, Sree Chitra Tirunal Institute for Medical Science and Technology, Thiruvananthapuram, 695012, Kerala, India.
Harikrishnan Vijayakumar SreelathaDivision of Laboratory Animal Science, Department of Applied Biology, Biomedical Technology Wing, Sree Chitra Tirunal Institute for Medical Science and Technology, Thiruvananthapuram, 695012, Kerala, India.
Sabareeswaran ArumugamDivision of Experimental Pathology, Department of Applied Biology, Biomedical Technology Wing, Sree Chitra Tirunal Institute for Medical Science and Technology, Thiruvananthapuram, 695012, Kerala, India.
Naresh KasojuDivision of Tissue Culture, Department of Applied Biology, Biomedical Technology Wing, Sree Chitra Tirunal Institute for Medical Science and Technology, Thiruvananthapuram, 695012, Kerala, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionPulmonary fibrosis, a condition characterized by excessive lung tissue scarring, remains a significant therapeutic challenge. Given the potential of human Wharton's jelly- derived mesenchymal stem cells (hWJ-MSCs) and their small extracellular vesicles (hWJ-MSC- EVs) as minimally invasive and scalable therapeutic options for pulmonary fibrosis in clinical settings, this study investigates the potential of hWJ-MSCs and hWJ-MSC-EVs in mitigating bleomycin-induced lung injury in C57BL/6J mice.

methodshWJ-MSCs were cultured and characterized for their ability to differentiate into osteogenic, adipogenic, and chondrogenic lineages. EVs were successfully induced via serum starvation, purified using ultracentrifugation, and characterized for their protein and nucleic acid content, size distribution, and EV markers. A bleomycin-induced pulmonary fibrosis model was established in C57BL/6J mice. Mice were monitored for weight loss, mortality, and lung fibrosis severity following treatment with hWJ-MSCs and hWJ-MSC-EVs. Histological analysis and Ashcroft scoring were used to assess lung fibrosis.

resultsBleomycin administration in mice resulted in significant weight loss, increased mortality, and severe lung fibrosis, as demonstrated by histological analysis and Ashcroft scoring. Treatment with hWJ-MSCs and hWJ-MSC-EVs significantly alleviated these symptoms. Mice receiving these treatments exhibited improved body weight, enhanced survival rates, and reduced lung fibrosis, with notable improvements in alveolar structure and decreased fibrotic tissue deposition.

conclusionThese findings highlight the potential of hWJ-MSCs and hWJ-MSC-EVs as therapeutic agents in treating pulmonary fibrosis by reducing inflammation and promoting lung tissue repair, offering a potential new avenue for regenerative therapy in severe lung diseases. Future research directions involve elucidating the molecular pathways involved in tissue repair, optimizing therapeutic delivery, and conducting comprehensive clinical evaluations.

Indexed as

Extracellular VesiclesLung InjuryMesenchymal Stem CellsMesenchymal Stem Cell TransplantationPulmonary FibrosisWharton JellyAnimalsBleomycinCell DifferentiationDisease Models, AnimalHumansMaleMiceMice, Inbred C57BLBleomycinbiotherapeutics.bleomycin-induced lung injuryextracellular vesicleshistomorphometric analysisHuman wharton’s jellymesenchymal stem cellspulmonary fibrosisregenerative medicine

Identifiers

PMID40289988

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.